Hemcheck has received a first evaluation order from the Heim Pál National Pediatric Institute in Budapest, Hungary. The order is of lower economic value, but there is an opportunity for more and larger orders. The order refers to hemolysis detection for diagnostic use.
– It is very positive to have Heim Pál as a customer, as it is a highly regarded children’s hospital in Hungary. We see continued strong interest from various hospitals that want to evaluate our products, and we hope that this order will be followed by more in the near future, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.